Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(50%)

Phase Distribution

Ph phase_4
1
50%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (100.0%)

Trials by Status

completed150%
terminated150%

Recent Activity

0 active trials
Showing 2 of 2
completed

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

NCT06130345
terminatedphase_4

COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

NCT05075538

Clinical Trials (2)

Showing 2 of 2 trials
NCT06130345

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

Completed
NCT05075538Phase 4

COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2

Terminated

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2